Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. (September 2017)

• Record Type: Journal Article
• Authors: Smith-Cohn, Matthew A; Gill, David; Voorhies, Benjamin N; Agarwal, Neeraj; Garrido-Laguna, Ignacio
• Is Part Of: Immunotherapy. Volume 9:Number 10(2017)
• Page Start: 797
• Page End: 804
• Publication Date: 2017-09
• Subjects: autoimmunity -- checkpoint inhibitors -- diabetes; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2017-0042
• Languages: English
• ISSNs: 1750-743X

Abstract

Background: Immune checkpoint inhibitors are novel cancer therapies associated with numerous autoimmune toxicities, some of which are only now being appreciated.Case presentation: A 67-year old female with metastatic cholangiocarcinoma and no prior history of diabetes was treated with leucovorin, fluorouracil, oxaliplatin and pembrolizumab. After eight cycles, she developed new onset type 1 diabetes mellitus with positive glutamic acid decarboxylase antibody titers. Conclusions: To our knowledge, this is the first reported case of PD-1 inhibitor associated Type 1 diabetes mellitus in a patient with cholangiocarcinoma and supports others' experiences that PD-1 inhibition can cause a spectrum of autoimmune adverse events that require clinical monitoring and periodic screenings.